The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
A real-world study compared the two chimeric antigen receptor (CAR) T-cell therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for the treatment of
Measurable residual disease (MRD) negativity was associated with better response to treatment with the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) in
The Japan Ministry of Health, Labour and Welfare has approved epcoritamab (Epkinly) as a treatment for adult patients with relapsed or refractory follicular
Axicabtagene ciloleucel (axi-cel) prolonged survival in large B-cell lymphoma (LBCL) compared with standard of care (SOC), and the ZUMA-7 trial also found that
Which therapies in top-line data show potential benefits for anemia compared to expected levels with JAK inhibition.
SOHO will hold its first regional meeting in Spain from February 27-28, 2025, at the Rafael del Pino Auditorium in Madrid. The program
Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a
Researchers assessed barriers to chimeric antigen receptor (CAR) T-cell therapy for patients with non-Hodgkin lymphoma (NHL) in a community-based network and found that
FDA accepts for review a BLA for Blenrep in combination with bortezomib plus dexamethasone and pomalidomide plus dexamethasone in MM.
A study showed that the triplet therapy isatuximab, pomalidomide, and dexamethasone (IsaPd) is an option for daratumumab-refractory multiple myeloma (MM), though the “modest”
